Discontinuation strategies and long-term outcome of antidepressant medications
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20233549Keywords:
Antidepressants, Antidepressant medications, Discontinuation strategies, Long-term outcomes, DepressionAbstract
In terms of the treatment of depression, it is proven by many research that antidepressant drug has a significant impact on the treatment of depression patients. They can make them feel better and cope with their challenges. However, discontinuing these medications can be challenging due to concerns such as relapse, withdrawal symptoms, recurrence, and patient preferences. In this paper, we conducted a review of research on strategies for stopping antidepressants. Explored their long-term effects. By analyzing randomized controlled trials, cohort studies, systematic reviews, and meta-analyses, we gained insights into discontinuation methods and the extended impact of antidepressant use. Findings from quality evidence suggest that abruptly stopping antidepressants increases the risk of relapse or recurrence compared to reducing dosage or continuing with medication. Similarly, reducing dosage gradually helps in decreasing the risk and severity of withdrawal symptoms when compared to discontinuation or continued use without tapering off. Furthermore, psychological interventions like therapy or mindfulness-based cognitive therapy are identified as a best protocol for preventing relapse or recurrence after discontinuing antidepressants. These interventions are found to be particularly effective for patients experiencing symptoms or having risk factors. Additionally, although there is evidence regarding the long-term outcomes of using antidepressants beyond two years, some studies suggest that additional interventions such as patient education, shared decision-making processes monitoring progress, and providing feedback can assist in supporting successful discontinuation by improving adherence and patient satisfaction. In summary, stopping antidepressant medication is a process that necessitates assessment.
Metrics
References
Blackburn TP. Depressive disorders: Treatment failures and poor prognosis over the last 50 years. Pharmacol Res Perspect. 2019;7(3):e00472.
Reddy MS. Depression: the disorder and the burden. Indian J Psychol Med. 2010;32(1):1-2.
Parish AL, Gillis B, Anthamatten A. Pharmacotherapy for Depression and Anxiety in the Primary Care Setting. J Nurse Pract. 2023;19(4):104556.
Brody DJ, Pratt LA, Hughes JP. Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013-2016. NCHS Data Brief. 2018(303):1-8.
Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020;3(9):e2019686.
Dzevlan A, Redzepagic R, Hadzisalihovic M, et al. Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/or Anxiety Disorder. Mater Sociomed. 2019;31(1):14-8.
Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother. 2009;9(7):975-84.
Unützer J, Park M. Strategies to improve the management of depression in primary care. Prim Care. 2012;39(2):415-31.
Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Cmaj. 2017;189(21):E747.
Horowitz MA, Framer A, Hengartner MP, Sørensen A, Taylor D. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data. CNS Drugs. 2023;37(2):143-57.
Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag. 2008;4(1):269-86.
Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155-9.
Van Leeuwen E, van Driel ML, Horowitz MA. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev. 2021;4(4):Cd013495.
Huijbers MJ, Wentink C, Simons E, Spijker J, Speckens A. Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers. BMJ Open. 2020;10(11):e039053.
Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019;116(20):355-61.
Liu X, Momen NC, Molenaar N, Rommel AS, Bergink V, Munk-Olsen T. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? J Affect Disord. 2021;290:254-60.
Barnard K, Peveler RC, Holt RI. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care. 2013;36(10):3337-45.
Stutzman DL. Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing. Ment Health Clin. 2021;11(6):320-33.
Kendrick T, Geraghty AWA, Bowers H, Stuart B, Leydon G, May C, et al. REDUCE (Reviewing long-term antidepressant use by careful monitoring in everyday practice) internet and telephone support to people coming off long-term antidepressants: protocol for a randomised controlled trial. Trials. 2020;21(1):419.
Kato M, Hori H, Inoue T, Iga J, Iwata M, Inagaki T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(1):118-33.
Marloes JH, Carolien W, Esther S, Jan S, Anne S. Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers. BMJ Open. 2020;10(11):e039053.
Hofmann SG, Gómez AF. Mindfulness-Based Interventions for Anxiety and Depression. Psychiatr Clin North Am. 2017;40(4):739-49.